Home Conference Coverage

Conference Coverage

Photo: Photo ASCO meeting. Photo Courtesy: ASCO/Todd Buchanan 2015

ASCO 2020 – Promising Development in the Advancement of Antibody-drug Conjugates

With an increasing number of antibody-drug conjugates (ADC) being approved and commercially available for the treatment of patients with...

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits...
Featured Image: Better times - ASCO | McCormick Place. Courtesy: © 2017 Fotolia. Used with permission.

ASCO 2020 – Advancing Antibody-drug Conjugates: Belantamab Mafodotin

Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable. Research into...

ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent Ovarian Cancer

Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853),...
Daiichi Sankyo

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for HER2...

In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to...
The AACR Annual Meeting in better times - before COVID19: the AACR annual meeting opening plenary session in 2018 at the McCormick Convention Center in Chicago, Illinois with the 2019 president-elect Elaine Mardis, Ph.D, who served as program committee chair for this 2018 meeting, addressed attendees. Photo Courtesy © AACR/Todd Buchanan.

AACR 2020: Phase I Clinical Trial with STRO-002 Shows Encouraging Interim Dose-escalation Data...

Updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from an on-going...

Growing Number of Major Medical Meetings Cancelled – AACR and Others Postponed

The novel coronavirus, also known as COVID19, is prompting major medical societies and healthcare organizations to cancel conferences and...

Sutro Presents Innovative Cancer Therapy Approach Using Tumor Targeted Immunostimulants

A proof of concept for a next-generation dual conjugated combination immunostimulatory antibody-drug conjugate (IADC) was release by Sutro Biopharma,...

Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink Tumors in the...

Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with...

Next Generation Immunotherapies

The immune system has already provided a number of potent strategies for treating cancers that are already impacting clinic,...